Excessive daytime sleepiness, morning tiredness, and prognostic biomarkers in patients with chronic coronary syndrome
Copyright © 2023 The Authors. Published by Elsevier B.V. All rights reserved..
BACKGROUND: Sleep-related breathing disorders (SRBD) are related to cardiovascular outcomes in patients with chronic coronary syndrome (CCS). Whether SRBD-related symptoms are associated with prognostic biomarkers in patients with CCS is not established.
METHODS: Associations between frequency (never/rarely, sometimes, often, always) of self-reported SRBD-related symptoms (excessive daytime sleepiness [EDS]; morning tiredness [MT]; loud snoring; multiple awakenings/night; gasping, choking, or apnea when asleep) and levels of biomarkers related to cardiovascular prognosis (high-sensitivity C-reactive protein [hs-CRP], interleukin 6 [IL-6], high-sensitivity cardiac troponin T [hs-cTnT], N-terminal pro B-type natriuretic peptide [NT-proBNP], cystatin C, growth differentiation factor 15 [GDF-15] and lipoprotein-associated phospholipase A2 activity) were assessed at baseline in 15,640 patients with CCS on optimal secondary preventive therapy in the STABILITY trial. Cross-sectional associations were assessed by adjusted linear regression models testing for trends with the never/rarely category serving as reference.
RESULTS: EDS was associated (geometric mean ratio, 95% confidence interval) with increased levels of IL-6 (often 1.07 [1.03-1.10], always 1.15 [1.10-1.21]), GDF-15 (often 1.03 [1.01-1.06], always 1.07 [1.03-1.11]), NT-proBNP (always 1.22 [1.12-1.33]), and hs-cTnT (always 1.07 [1.01-1.12]). MT was associated with increased levels of IL-6 (often 1.05 [1.01-1.09], always 1.09 [1.04-1.15]), and GDF-15 (always 1.06 [1.03-1.10]). All symptoms were to some degree associated with higher levels of hs-CRP and loud snoring was also associated with decreased levels of NT-proBNP and hs-cTnT.
CONCLUSIONS: In patients with CCS, stepwise increased frequency of SRBD-related symptoms, such as EDS and MT, were associated with gradually higher levels of IL-6 and GDF-15, each reflecting distinct pathophysiological pathways.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 2023 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:394 |
|---|---|
| Enthalten in: |
International journal of cardiology - 394(2023) vom: 01. Jan., Seite 131395 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Olszowka, Maciej [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 04.12.2023 Date Revised 04.12.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.ijcard.2023.131395 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM362449031 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM362449031 | ||
| 003 | DE-627 | ||
| 005 | 20231226091251.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.ijcard.2023.131395 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1208.xml |
| 035 | |a (DE-627)NLM362449031 | ||
| 035 | |a (NLM)37748524 | ||
| 035 | |a (PII)S0167-5273(23)01388-8 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Olszowka, Maciej |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Excessive daytime sleepiness, morning tiredness, and prognostic biomarkers in patients with chronic coronary syndrome |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 04.12.2023 | ||
| 500 | |a Date Revised 04.12.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 The Authors. Published by Elsevier B.V. All rights reserved. | ||
| 520 | |a BACKGROUND: Sleep-related breathing disorders (SRBD) are related to cardiovascular outcomes in patients with chronic coronary syndrome (CCS). Whether SRBD-related symptoms are associated with prognostic biomarkers in patients with CCS is not established | ||
| 520 | |a METHODS: Associations between frequency (never/rarely, sometimes, often, always) of self-reported SRBD-related symptoms (excessive daytime sleepiness [EDS]; morning tiredness [MT]; loud snoring; multiple awakenings/night; gasping, choking, or apnea when asleep) and levels of biomarkers related to cardiovascular prognosis (high-sensitivity C-reactive protein [hs-CRP], interleukin 6 [IL-6], high-sensitivity cardiac troponin T [hs-cTnT], N-terminal pro B-type natriuretic peptide [NT-proBNP], cystatin C, growth differentiation factor 15 [GDF-15] and lipoprotein-associated phospholipase A2 activity) were assessed at baseline in 15,640 patients with CCS on optimal secondary preventive therapy in the STABILITY trial. Cross-sectional associations were assessed by adjusted linear regression models testing for trends with the never/rarely category serving as reference | ||
| 520 | |a RESULTS: EDS was associated (geometric mean ratio, 95% confidence interval) with increased levels of IL-6 (often 1.07 [1.03-1.10], always 1.15 [1.10-1.21]), GDF-15 (often 1.03 [1.01-1.06], always 1.07 [1.03-1.11]), NT-proBNP (always 1.22 [1.12-1.33]), and hs-cTnT (always 1.07 [1.01-1.12]). MT was associated with increased levels of IL-6 (often 1.05 [1.01-1.09], always 1.09 [1.04-1.15]), and GDF-15 (always 1.06 [1.03-1.10]). All symptoms were to some degree associated with higher levels of hs-CRP and loud snoring was also associated with decreased levels of NT-proBNP and hs-cTnT | ||
| 520 | |a CONCLUSIONS: In patients with CCS, stepwise increased frequency of SRBD-related symptoms, such as EDS and MT, were associated with gradually higher levels of IL-6 and GDF-15, each reflecting distinct pathophysiological pathways | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Biomarkers | |
| 650 | 4 | |a Cardiovascular risk factors | |
| 650 | 4 | |a Coronary heart disease | |
| 650 | 4 | |a Sleep disorders | |
| 650 | 7 | |a C-Reactive Protein |2 NLM | |
| 650 | 7 | |a 9007-41-4 |2 NLM | |
| 650 | 7 | |a Growth Differentiation Factor 15 |2 NLM | |
| 650 | 7 | |a Interleukin-6 |2 NLM | |
| 650 | 7 | |a Biomarkers |2 NLM | |
| 650 | 7 | |a Natriuretic Peptide, Brain |2 NLM | |
| 650 | 7 | |a 114471-18-0 |2 NLM | |
| 650 | 7 | |a Peptide Fragments |2 NLM | |
| 650 | 7 | |a Troponin T |2 NLM | |
| 700 | 1 | |a Hagström, Emil |e verfasserin |4 aut | |
| 700 | 1 | |a Hadziosmanovic, Nermin |e verfasserin |4 aut | |
| 700 | 1 | |a Ljunggren, Mirjam |e verfasserin |4 aut | |
| 700 | 1 | |a Denchev, Stefan |e verfasserin |4 aut | |
| 700 | 1 | |a Manolis, Athanasios |e verfasserin |4 aut | |
| 700 | 1 | |a Wallentin, Lars |e verfasserin |4 aut | |
| 700 | 1 | |a White, Harvey D |e verfasserin |4 aut | |
| 700 | 1 | |a Stewart, Ralph A H |e verfasserin |4 aut | |
| 700 | 1 | |a Held, Claes |e verfasserin |4 aut | |
| 700 | 0 | |a STABILITY Investigators |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t International journal of cardiology |d 1984 |g 394(2023) vom: 01. Jan., Seite 131395 |w (DE-627)NLM012621196 |x 1874-1754 |7 nnns |
| 773 | 1 | 8 | |g volume:394 |g year:2023 |g day:01 |g month:01 |g pages:131395 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.ijcard.2023.131395 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 394 |j 2023 |b 01 |c 01 |h 131395 | ||